

Remarks

The specification has been amended to include a claim to priority in compliance with 35 U.S.C. §119(e), and an abstract in compliance with 37 C.F.R. §1.72(b). Claims 5-7 and 29-32 are amended and new Claims 34-54 are added to remove the multiple dependency of claims dependent from multiply dependent claims. Claim 8 is cancelled without prejudice in favor of new Claim 55, which takes into account new Claims 34-54. Claims 15-26 have been cancelled without prejudice in that they are drawn to pharmaceutical uses in claim formats not favored under U.S. patent law, and in that their subject matter is otherwise effectively protected by the corresponding method of treatment claims, Claims 9-14. New Claims 56-58 are directed to particular preferred embodiments of the invention as set further in the Specification, particularly at examples 8, 22, and 23. No new subject matter is added.

Respectfully submitted,



R. Craig Tucker
Attorney for Applicants
Registration No. 45,165
Phone: 317-433-9829

Eli Lilly and Company
Patent Division / RCT
P.O. Box 6288
Indianapolis, Indiana 46206-6288

Sept 2, 2004